ity remains among vulnerable populations. The SDP rate is higher among pregnant women who are younger, less educated, socioeconomically disadvantaged, and residents of rural areas, compared with other expectant mothers. [1] [2] [3] Tobacco retailer density (TRD) has been linked to high smoking rates, increased cigarette intake, low life expectancy, and high mortality. 4, 5 The number of tobacco retailers in the southeast United States increased by approximately 8300 in late 2012 and early 2013, when Family Dollar and Dollar General, the 2 largest dollar-store chains in the country, started selling tobacco products to meet customer demand. The number of tobacco retailers in the southeast decreased in 2014 by approximately 2500 when CVS, the largest pharmacy chain, discontinued tobacco sales. The fluctuation in TRD has affected communities differently, as CVS pharmacies are more likely to be located in urban areas, whereas dollar stores are more likely to operate in poor and rural communities. 6 In this study, we examined the association between change in SDP and corporate-policy change in TRD across 6 southeastern states, controlling for rurality, poverty, social vulnerability, and tobacco-control policies. All 6 states included in this study-Florida, Georgia, Mississippi, North Carolina, South Carolina, and Tennessee-declined to adopt the Affordable Care Act Medicaid expansion in 2014, limiting access to smoking cessation and contraception programs among these states' low-income populations. Abbreviations: ANOVA, analysis of variance; SDP, smoking during pregnancy; SES, Socioeconomic Status Index; SVI, Social Vulnerability Index; TRD, tobacco retailer density. a To account for the instability resulting from counties with very low populations, 149 counties with a 2016 population of fewer than 20 000 were merged with an adjacent contiguous county within the same rurality category. b Rurality categories for each county followed the National Center for Health Statistics classifications (code 1-2, urban; code 3-4, small metropolitan; code 4-6, rural). c SES-SVI (CDC/ATSDR SVI; https://svi.cdc.gov); SES is 1 of the 4 indexes used to create the SVI composite index. The higher the SES vulnerability, the higher the SES score on this index. d State-level expenditures on tobacco-control efforts were from State Tobacco Activities Tracking and Evaluation system.
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Methods | This retrospective study used open outcomes data aggregated at the county level, which are published and made available online by the state health departments of Florida, Georgia, Mississippi, North Carolina, South Carolina, and Tennessee. As such, no institutional review board approval and informed consent were required. Annual county-level birth and self-reported SDP counts (from birth registries) between January 1, 2011, and December 31, 2016, were obtained from public-facing websites of state health departments. Addresses of CVS pharmacies and dollar stores in the region (as of January 1, 2018) were identified from corporate websites. County-level TRD change resulting from corporate policy was calculated as the number of dollar stores minus the number of CVS pharmacies per 10 000 adults. Percentage change in SDP was calculated for 2011 to 2012 and for 2015 to 2016 (before and after the corporate policy changes). We examined the association between percentage change in SDP and TRD change at the county level using a mixed-effects regression model. Control variables included socioeconomic vulnerability (Socioeconomic Status Index, 1 of the 4 components of the Centers for Disease Control and Prevention Social Vulnerability Index), rurality, existence of smoke-free law, and state.
With analysis of variance, we compared county-level percentage change in SDP across categories of rurality and socioeconomic vulnerability (below and above the southeast US median) and in states with high or low tobacco-control funding. All analyses were conducted with SAS, version 9.4 (IBM), and 2-sided P < .05 was used to indicate statistical significance.
Results | Across the 6-state region, SDP decreased 15.6% between 2011 to 2012 and 2015 to 2016. The contrasting policy changes by the dollar stores and by CVS yielded an overall TRD increase in the 6 states of 1.0 additional store per 10 000 adults. The TRD change was 2.7 more stores per 10 000 adults in counties with high TRD increase and was 0.6 additional stores per 10 000 adults in counties with low TRD increase. Difference in percentage change in SDP between counties experiencing high TRD change and those experiencing low TRD change was statistically significant (-5.0 vs -19.0; P < .001) as well as across all rurality categories and socioeconomic vulnerability categories ( Table 1 ). In the mixed-effects model, county-level TRD increase (t = 2.81; P = .005) as well as socioeconomic vulnerability (t = 1.89; P = .06) and rurality (t = -2.69; P = .007) were the most important indicators of the magnitude of SDP decrease, whereas tobacco-control measures did not seem associated with improvement in SDP during the study period ( Table 2) .
Discussion | In this study, we identified an association of SDP with increased TRD after corporate sales decisions. The decision by CVS to discontinue selling tobacco was followed by a reduction of TRD in some counties, but the initiation of tobacco sales by dollar stores has increased access to tobacco products across the region. We examined several of the largest contributing factors to SDP and found that high TRD may be inhibiting progress in smoking reduction across the southeast, regardless of rurality, socioeconomic vulnerability, and ongoing tobacco-control efforts. Localities could look into licensing and zoning as lasting strategies to reduce TRD, and states should adequately fund smoking-cessation and health communications interventions with a mass reach. b Refers to laws pertaining to smoke-free restaurant and workplace regulations in states, counties, and municipalities (binary variable indicating if a county, or the largest city of a county, had any smoke-free workplace law). c Rurality, a binary variable, was used to control for urban and nonurban differences (National Center for Health Statistics code 1-2 for urban). d A categorical variable for state was included to control for any other state-level policy differences that might affect the association between percentage change in SDP and TRD change (ie, differences in state-level taxes and tobacco-control funding). Georgia was chosen as the reference state for its lowest overall rates of self-reported SDP.
Association of Maternal Probiotic Supplementation With Human Milk Oligosaccharide Composition
Human milk oligosaccharides (HMOs) are complex glycans and the third-largest solid component in human milk. They are typically nondigestible by humans but are a major substrate for infants' gut microbiota and affect the maturation of the intestinal mucosal immune system. All HMOs are extensions of lactose generated by the action of a series of glycosyltransferases. Depending on the mother's Secretor and Lewis blood groups, the fucosyltransferases FUT2 (the Secretor gene) and/or FUT3 (the Lewis gene) are available for the synthesis of HMOs. The resulting heterogeneity implies that some breastfed infants are not being exposed to certain structures, which may affect their microbiome composition and thereby disease risk for illnesses in which gut microbiome plays a role. Infants fed by mothers who lack a Secretor gene and therefore lack a functional FUT2 enzyme and all α-1-2-fucosylated oligosaccharides have delayed development of bifidobacteria-laden microbiota. 1 Also, if these infants are born via cesarean delivery, they have a higher risk to manifest IgE-associated eczema. 2 We recently showed that certain HMOs are associated with protection against cow-milk allergy in infants. 3 Besides genetic differences that are responsible for differences in HMO profiles, HMO abundance changes throughout lactation. 4 However, no other factors have been associated with variation in HMO abundances. This study sought to assess the association of maternal probiotic supplementation with HMO concentrations.
Methods | We used stored frozen colostrum samples from a previously published large, double-blind, placebo-controlled randomized clinical trial 5,6 of probiotic supplementation study of 1223 pregnant mothers from Helsinki, Finland, carrying fetuses at hereditary risk for allergy (ie, the offspring had 1 or both parents with physician-diagnosed allergic rhinitis, eczema, and/or asthma). The children born to these mothers were followed up for 10 years for the development of allergic disease. In the probiotic group, mothers took twice-daily doses of Lactobacillus rhamnosus GG, Lactobacillus rhamnosus LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii subspecies shermanii JS in capsules from 36 weeks' gestation until the birth of the infant. Mature milk samples were available for more than 500 mothers; we randomly selected 81 colostrum samples (stored frozen at −62.2°C), with 30 samples from the placebo group and 51 from the probiotic group. There was an equal distribution of tobacco-smoking mothers and mothers with a history of atopic disease between the 2 groups. The concentrations of 19 HMOs were determined using high-performance liquid chromatography after 2-aminobenzamide labeling. 3 Raffinose was added to milk samples as an internal standard to allow for absolute quantification. Freezing does not affect HMO levels, which are very stable in full-term milk from day to day and diurnally.
4
The study was approved by the institutional review board of the Hospital for Children and Adolescents, Helsinki University Central Hospital, Finland. All mothers signed a written informed consent form.
Statistical analysis was carried out using R software version 3.5.0 (R Foundation for Statistical Computing), and 2-sided P values less than .05 were considered significant in all com- However, mean [SD] levels of HMOs were lower in colostrum from mothers who received probiotic supplementation than in the control group; this was found in difucosyllacto-Nhexaose (probiotic group, 62.0 [43.4] 
